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1. Introduction 
Implantable cardioverter-defibrillator is largely used as an effective treatment for potentially 
lethal arrhythmias in adult population. On the contrary, just 1% of devices are implanted in 
pediatric population worldwide. In our series, 4% of defibrillators implanted between 2000 
and 2010 were in children under 18 years of age.  
During the last two decades, prevention and treatment decisions in pediatric population 
have been commonly made on adult data, including device therapy recommendations. 
Indeed, most pediatric data comes from single-center series and case reports, with no 
specific clinical trials focused on this population.  
The incidence of pediatric sudden cardiac death is estimated at 1.3-8.5:100.000 patients-years 
(William et al., 1998). Survival of out-hospital cardiac arrest is as low as 8-9% and 
neurological sequels remain high (Driscoll et al., 1985). Sudden cardiac death in childhood 
and adolescence is associated with three main cardiovascular conditions: congenital heart 
diseases, cardiomyopathies, and genetic arrhythmia syndromes. In this setting, implantable 
defibrillator has become an effective antiarrhythmic therapy in a large variety of structural 
cardiovascular abnormalities and primary electrical diseases.  
Device implantation in children is challenging because of peculiar patient characteristics 
as age, weight, vascular access and potential somatic growth. Therefore, procedural 
approach and site of implantation, therapeutic algorithms and early and long-term 
complications differ from adults. Transvenous approaches could be difficult because of 
small venous system (Radbill et al., 2010). Abdominal implantation of generator and 
epicardial leads are frequently needed. Early physical activity and impaired sterile 
conditions added to individual characteristic are related to more frequent procedural 
complications (Shah, 2009).  
Device dysfunction, i.e. inappropriate therapies may appear frequently, between 11% and 
50% of cases, in the settings of sinusal and supraventricular tachycardia or T wave 
oversensing (Korte et al., 2004). Several algorithms have been used to reduce 
inappropriate discharges, as QRS discrimination or cardiac rate stability (Barry et al., 
2001). Lead complications are related to high physical activity and body surface, 
significantly higher in patients with body area under 1.2 m2 (OR 4.5) (Shah, 2009).  
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Psychological impact of defibrillator implantation and discharges during follow up may 
lead into more frequent depression and anxiety symptoms than in adult patients (Sears et 
al., 2011). Screening of inherited arrhythmic conditions in relatives of children carrying a 
defibrillator may be useful to detect potential risk in these relatives. Tomaske et al., 2011, 
reported 22% appropriate shocks in defibrillators implanted for primary prevention in this 
population. 
2. Sudden cardiac death in children 
Sudden cardiac death is defined as an abrupt, unexpected death occurring within 1 hour 
from the onset of cardiovascular symptoms. In young people, it typically occurs within a 
few minutes of symptoms onset. Aborted cardiac arrest includes cardiac resuscitation 
restoring spontaneous circulation. Excluding the Sudden Infant Death Syndrome, that 
affects children under 1 year, with an incidence around 1–1.5/1.000 infants, sudden death in 
a young person is a rare event (Gajewski et al., 2010). The estimated incidence of pediatric 
sudden cardiac death ranges from 1.3 to 8.5 per 100,000 children in the United States 
(Driscoll et al., 1985) (William et al., 1998). Approximately 20–25% of the deaths occur 
during sports (Liberthson et al., 1996). In patients with congenital heart disease, this rate 
increases to 100 deaths per 100,000 patients (O’Connor et al., 1998). Early cardiopulmonary 
resuscitation and extended availability of automatic external defibrillators could prevent 
about a quarter of pediatric sudden deaths (Gajewski and Saul, 2010). Since most sudden 
deaths have a cardiovascular cause, it is theoretically possible to identify patients at risk 
prior to the event and prevent it (Haskell et al., 2010).  
 
Causes of sudden cardiac death Relative incidence 
(%)
Hypertrophic cardiomyopathy 36
Increased cardiac mass 10
Coronary arteries anomalies 24
Marfan's Syndrome 6
Congenital heart disease 5
Myocarditis 3
Dilated cardiomyopathy 3
Arrhythmogenic right ventricular 
dysplasia 
3
Ischemic heart disease 2
Commotio cordis <1
Table 1. Causes of sudden cardiac death in children. Taken from Maron et al. JAMA. 1996. 
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Most young people with sudden cardiac death have an underlying heart condition, with 
hypertrophic cardiomyopathy, coronary artery anomalies, arrhythmogenic right ventricular 
dysplasia and long QT syndrome being commonest in most series (Silka et al., 1991, Maron 
et al. 1996a).  
Hypertrophic cardiomyopathy is the most common cause of sudden unexpected death in 
childhood, significantly higher in the 8- to 16-year age range than in the 17- to 30-year 
(Maron et al., 1996a). Disease prevalence is as high as 1 per 500 in young adults (Maron et 
al., 1996b), (Corrado et al., 1998). Carriers of a genetic mutation may have little or no 
hypertrophy, especially earlier in life. Sudden death is often exertional and secondary to 
malignant ventricular arrhythmias. Lipophilic betablocker, disopiramid and implantable 
cardioverter-defibrillator have demonstrated to increase survival in this population.  
Arrhythmia in children with dilated cardiomyopathy is one major clinical manifestation of 
the disease. The occurrence of arrhythmia is associated with the left ventricular size and 
heart function and includes ventricular ectopy (Han et al., 2011). An underlying myocarditis 
is found in 2-15% of patients, rising to 45% in a series of patients under 2 years, with other 
25% affected by endomyocardial fibrosis (Meune et al. 2006). Other conditions as infectious, 
metabolic and neurological diseases have been described as causes of dilated 
cardiomyopathy. 20-25% of cases are inherited. Dilated cardiomyopathy is progressive, 
often clinically silent in childhood, and sudden cardiac death may occur prior to 
development of heart failure symptoms.  
Left ventricular hypertrabeculation/noncompaction is a genetic myocardiopathy affecting 
line-Z skeletal and cardiac contractile proteins. In children, it is found in 0,01% of 
echocardiographic explorations, meaning 10% of pediatrical cardiomyopathies (Pignatelli et 
al., 2003). In pediatric population, diagnosis is usually made within first three months of life. 
Sustained or non-sustained ventricular tachycardia is seen in 40% of patients, and in 14% of 
patients QT interval is prolonged. Ventricular fibrillation is more frequent in children than 
in adults (Stöllberger et al., 2010). Almost 20% of patients with ventricular tachycardia or 
fibrillation have a normal systolic function. Data about long-term follow-up of patients with 
implanted cardioverter-defibrillator is necessary since indication for prophylactic 
implantation is still unclear.  
The incidence of sudden death in patients with congenital heart disease is about 100/100,000 
patient-years (O’Connor et al., 1998). It is higher in cyanotic and left heart obstructive 
lesions, may be due to arrhythmic, embolic or circulatory phenomena. Certain congenital 
defects have a higher risk of acquired arrhythmias following repair. The risk of sudden 
death appears to increase with age and time from surgery. Specifically, tetralogy of Fallot is 
associated with high incidence of ventricular tachycardia and 0.5% to 6% risk of sudden 
cardiac death (Gajewski et al., 2010). Patients with both single-ventricle physiology status-
post Fontan, and transposition of the great arteries status-post atrial switch also have high 
acquired arrhythmia rates with increased incidence of sudden cardiac death. These two 
congenital cardiac conditions may lead to the implantation of a cardioverter-defibrillator as 
a primary prevention strategy. 
Arrhythmogenic right ventricular dysplasia is a rare cause of sudden cardiac death in the 
United States, but is reported as the most common cause of sudden cardiac death in the 
young athletes in Italy (Maron et al., 2009), (Corrado et al., 2009). It is a heritable, 
progressive cardiomyopathy characterized by fatty and fibrous replacement of the 
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myocardium, causing thinning of right ventricular free wall. Although both drug therapy 
and catheter ablation are occasionally successful, implantation of a defibrillator is usually 
recommended for patients with significant symptoms. 
A variety of conditions can cause primary arrhythmia in young people: Long QT Syndrome, 
Brugada Syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia, Wolff-
Parkinson-White Syndrome, and Congenital Complete Heart Block. Although there are 
cases in which sudden cardiac death is the first symptom, recurrent syncope often precedes 
malignant events (Proclemer et al., 2009). Fortunately, the surface 12-lead ECG is abnormal 
in most cases.  
The congenital form of Long QT syndrome is a familial genetic disorder occurring about 1 in 
2.500–3.500 individuals (Vincent et al., 1992). It manifests primarily as ventricular 
repolarization abnormalities caused by cardiac ion-channel mutations. For symptomatic 
patients, the presenting symptom is usually syncope, due to torsade-de-pointes ventricular 
tachycardia. The syncope may occur with specific triggers, such as stress, swimming, and 
loud auditory stimuli, or it may occur when the child is relatively bradycardic, at resting or 
sleeping (Schwartz et al., 2001). The specific phenotype (LQTS1, LQTS2 and LQTS3) can be 
predicted from the genetic mutation and may help in the assessment of risk for sudden 
death or response to therapy (Tester et al., 2005). Main therapy remains beta-blockade, 
which is less effective for LQTS3. If symptoms recur under beta-blocker therapy, 
implantation of a cardioverter-defibrillator is generally indicated. 
Brugada syndrome is an inherited arrhythmogenic syndrome related to life-threatening 
ventricular arrhythmia due to a mutation in genes encoding sodium-channels (Miyamoto et 
al., 2011). Family sudden death history does not predict higher ventricular arrhythmia 
susceptibility (Delise et al., 2010). Treatment is limited to ICD implantation when symptoms 
like syncope occur. 
Catecholaminergic polymorphic ventricular tachycardia is a genetic arrhythmogenic disease 
caused by mutations in genes encoding sarcoplasmic calcium ion-channels (Tester et al., 
2006). Ventricular ectopy induced by exercise or emotional stress is typically observed. The 
onset of symptoms typically occurs in childhood and adolescence. Left untreated, 
Catecholaminergic Polymorphic Ventricular Tachycardia is lethal in 30–50% of patients 
(Leenhardt et al., 1995). Although beta-blockers are the recommended therapy, many 
patients present with recurrent arrhythmic symptoms and may need a defibrillator. 
3. Cardioverter-defibrillator in pediatric population 
3.1 Indications 
For the last decade, use of implantable cardioverter-defibrillator in children has increased 
dramatically. The number of pediatric implants per year has augmented by three-fold. The 
mean age at implant has decreased significantly (from 13.6 to 12.2 years), and the percentage 
of patients younger than 5 years of age receiving an implantable defibrillator tended to 
increase up to 10% (Burns et al., 2011). A large variability in the number of implants per 
center and year is observed and this situation may have implications for competency and 
training.  
Specific pediatric recommendations have been included in the ACC/AHA/HRS 2008 
Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities (Ebstein et al., 
2008): 
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Class I  ICD implantation is indicated in the survivor of cardiac arrest after 
evaluation to define the cause of the event and to exclude any 
reversible causes. Level of Evidence : B 
 ICD implantation is indicated for patients with symptomatic sustained 
VT in association with congenital heart disease who have undergone 
hemodynamic and electrophysiological evaluation. Catheter ablation 
or surgical repair may offer possible alternatives in carefully selected 
patients. Level of Evidence : C 
Class IIa  ICD implantation is reasonable for patients with congenital heart 
disease with recurrent syncope of undetermined origin in the presence 
of either ventricular dysfunction or inducible ventricular arrhythmias 
at electrophysiological study. Level of Evidence : B 
Class IIb  ICD implantation may be considered for patients with recurrent 
syncope associated with complex congenital heart disease and 
advanced systemic ventricular dysfunction when invasive and 
noninvasive investigations have failed to define a cause. Level of 
Evidence : C  
Class III  ICD therapy is not indicated for patients who do not have a 
reasonable expectation of survival with an acceptable functional status 
for at least 1 year, even if they meet criteria specified in the Class I, IIa, 
and IIb recommendations above. Level of Evidence : C. 
 ICD therapy is not indicated for patients with incessant VT or VF. 
Level of Evidence : C 
 ICD therapy is not indicated in patients with significant psychiatric 
illnesses that may be aggravated by device implantation or that may 
preclude systematic follow-up. Level of Evidence : C 
 ICD therapy is not indicated for NYHA Class IV patients with drug-
refractory congestive heart failure who are not candidates for cardiac 
transplantation or CRT-D. Level of Evidence : C 
 ICD therapy is not indicated for syncope of undetermined cause in a 
patient without inducible ventricular tachyarrhythmias and without 
structural heart disease. Level of Evidence : C 
 ICD therapy is not indicated when VF or VT is amenable to surgical or 
catheter ablation (e.g., atrial arrhythmias associated with the Wolff-
Parkinson-White syndrome, RV or LV outflow tract VT, idiopathic VT, 
or fascicular VT in the absence of structural heart disease). Level of 
Evidence : C 
 ICD therapy is not indicated for patients with ventricular 
tachyarrhythmias due to a completely reversible disorder in the 
absence of structural heart disease (e.g., electrolyte imbalance, drugs, 
or trauma). Level of Evidence : B 
Table 2. 
Indications for implantation of cardioverter-defibrillator in children over last two decades 
are based on clinical trials designed and performed for adult population. Indications are 
shifting from secondary to primary prevention. In fact, secondary prevention implants 
decreased significantly when compared to primary prevention from 77% to 45% (Burns et al., 
2011). In the Spanish Registry of Cardioverter-Defibrillator implantation, prophylactic 
implantation increased from 2006 to 2008 for Arrhythmogenic Right Ventricular Dysplasia 
and Brugada syndrome, with no increase for Long QT syndrome and hypertrophic  
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cardiomyopathy (Peinado et al., 2008). Primary prevention of sudden cardiac death remains 
a challenge in which individualized decisions play a mayor role. The low use of 
cardioverter-defibrillator in pediatric population difficult the assessment of cardioverter-
defibrillator survival benefit and long term results.  
In 1991, Silka et al. reported a series of 177 patients under 20 years in which a implantable 
cardioverter-defibrillator was indicated. 75% patients were survivors of sudden cardiac 
death, 10% had drug-refractory ventricular tachycardia and 10% syncope with positive 
electrophysiology study for arrythmia-inducibility. Almost 60% had an overt cardiovascular 
disease, whereas 26% had primary electrical condition and 18% congenital cardiopathy. 
Hypertrophic and dilated cardiomyopathies, transposition of great arteries and tetralogy of 
Fallot were commonest structural cardiac diseases. Systolic function was normal in 54% 
patients, and 48% had some degree of systolic function impairment. Von Berger et al., 2010 
reported an updated registry of 210 cardioverter-defibrillators implanted in patients under 
30 years-old in seven institutions between October 1992 and January 2007. Heart disease 
was categorized as electrical (n=90, 42%), cardiomyopathic (n=62, 30%), or congenital heart 
disease (n=58, 28%). 
In the Dutch Registry from 1995 to 2006 (Heersche, 2010), 45 cardioverter-defibrillator were 
implanted in children and young patients. According to indication, sudden death and 
ventricular tachycardia patients were similar to the American registry, with a higher rate of 
electrical conditions (55%) and prophylactic indication (17%). In the electrical disease group, 
56% had Long QT syndrome, 25% Idiopathic Ventricular Fibrillation and 19% Brugada 
Syndrome. Ten Harkell et al., 2006, reported another series of 23 Dutch pediatric defibrillator 
patients. 22% defibrillators were epicardial and 88% transvenous. The generator was placed in 
an abdominal position in 35% patients, whereas it was placed in the subpectoral region in 65%. 
There was no early mortality. Median hospital stay was 5 days.  
In our series, 11 cardioverter-defibrillators were implanted between 1995 and 2010 in 
patients under 18 years, 4% of all implanted defibrillators. 80% defibrillators were 
implanted for secondary prevention (Ventricular Fibrillation 60%, Ventricular Tachycardia 
20%) and 20% were implanted for primary prevention. Cardiac conditions were 40% Long 
QT Syndrome, 20% congenital cardiopathies, 10% hypertrophic cardiomyopathy, 10% 
hypertrabeculation/ Noncompactation cardiomyopathy and 20% had no overt structural 
heart disease. By age, long QT Syndrome was more frequent between younger patients, 
whereas transposition of Great Arteries was the commonest underlying cardiopathy in 15-18 
years-age group. 50% were single chamber devices and 50% dual chambers.  
 
 
Fig. 1. Comparison of three series of cardioverter-defibrillator implantation according to 
clinical presentation. Silka et al., 1991. Heersche et al., 2011. Granada, our series. 
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Fig. 2. Comparison of implantable cardioverter-defibrillation cardiac conditions in largest 
series. USA: Von Berger et al., 2010. Netherlands: Heersche et al., 2010. Granada, our 
series. 
The Italian Registry included pediatric defibrillator use in inherited arrhythmogenic 
diseases from 2001 to 2006 (Proclemer et el., 2009). For primary prevention, 30% defibrilators 
were implanted in Hypertrophic Cardiomyopathy, 16% in Arrhythmogenic Right 
Ventricular Dysplasia, 17% in idiopathic ventricular arrhythmia (they included Brugada 
Syndrome in this group) and 16% in the Long QT Syndrome. There were 52% single-
chamber, 44% dual-chamber, and 5% triple-chamber cardioverter-defibrillators. 
In terms of defibrillation energy required in pediatric patients, available data includes only 
external resuscitation devices. The recommended energy dose had been established in 2 
J/kg for the last 30 years, but recent reports may indicate that higher dosages may be more 
effective and safe. In 2005, the European Resuscitation Council recommended 4 J/kg as 
initial dose, without escalation for subsequent shocks (Haskell et al., 2010 & Sandroni et al., 
2011). 
3.2 Implantation techniques 
Despite the increasing use of implantable cardioverter-defibrillator in congenital heart 
patients, specific challenges and implications related to implantation and follow-up are 
continuously observed. The variability and complexity of congenital pediatric patients make 
device management a highly individualized art. There are technical issues related to 
implantation since vascular access and device characteristic may not be suitable for pediatric 
patient (Chun et al., 2008). Although advances in implantable cardioverter-defibrillator 
technology are constantly made, the optimal cardioverter-defibrillator implantation 
technique for pediatric patients has not been established yet. The implantation of 
cardioverter-defibrillator in pediatric patients has many peculiarities, and there is little 
information on implant methodology for this population. A statement on training pathways 
for implantation of cardioverter-defibrillators and cardiac resynchronization therapy 
devices in pediatric and congenital heart patients was published in 2008 (Saul et al., 2008).  
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
154 
Transvenous implantation in children presents multiple challenges, related to patient body 
surface and weight, physical activity, increased risk of infections, and long life expectancy. 
There are no specific electrodes for small vessel diameters, with the consequent risk of 
venous thrombosis, nor devices adapted to their body surface. The creation of an atrial loop 
might allow the ''elongation'' of the lead with the growth. Concerns have been raised about 
Long-term leads patency, ventricular and valvular dysfunction, venous integrity, cosmetic 
results and psychological factors. System survival rates are estimated at 91% for the first 
year from implant, 83% at 24 months and 76% at 36 months (Rabdill et al., 2010). 
 
  
Fig. 1. and 2. Frontal and lateral Rx of a dual-chamber cardioverter-defibrillator in a 10 
years-old patient with Brugada Syndrome. 
Nontransvenous implantable cardioverter-defibrillator systems include pericardial and 
subcutaneous coils as alternative approaches in selected pediatric and congenital heart 
patients who are not candidates for transvenous leads. These nontransvenous systems are 
more commonly used in younger patients, with smaller body surface area, intracardiac 
shunts and concurrent thoracotomy surgery or affection of thricuspid valve.  
Intrapericardial placement of an ICD coil system can be carried out through a subxiphoid 
approach and pericardial window without thoracotomy (Tomaske et al., 2008 & Bové et al., 
2010). This technique is independent from child size or cardiac status. The defibrillation coil 
lead is actively fixated in the transverse sinus under fluoroscopic guidance, and the 
generator placed in a subrectus pocket in the upper abdomen through the same incision. 
Epicardial system is effective in treating ventricular arrhythmia without inappropriate 
discharges and no perioperative complications nor early or late deaths have been reported 
(Hsia et al., 2009). Controversy remains about defibrillation thresholds, since Stephenson et 
al., described high defibrillation thresholds with epicardial leads (Stephenson et al., 2006) 
More recently, Silvetti reported, for a 20-months follow-up, impedance stability and 
acceptable defibrillation thresholds (5-15J) (Silvetti et al., 2007). 
Endocardial and epicardial steroid-eluting leads have comparable electrical performances, 
especially in absence of other congenital heart defects and previous heart surgery, although 
endocardial pacing shows the best outcomes and should be the first choice in children over 
10-15 kg (Chun et al., 2008). System survival is significantly shorter in nontransvenous than 
in transvenous systems at 12, 24, and 36 months (survival rates at 73%, 55%, and 49%, 
respectively) (Rabdill et al., 2010). In fact, nontransvenous systems have demonstrated to be 
an independent predictor of system failure.  
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Fig. 3. Dual-chamber epicardial leads cardioverter-defibrillator in a male 6 years-old patient 
with Tetralogy of Fallot.  
 
Fig. 4. Single-chamber epicardial cardioverter-defibrillator in a 2 years-old female child with 
Long QT Syndrome. See abdominal generator implantation, transverse sinus defibrillation 
coil and epicardial sense and pacing leads.  
One increasing option is totally extracardiac implantation. A subcutaneous implantable 
defibrillator does not require a lead placed on or in the heart (McLeod et al., 2010). It may 
become an option for children suffering from chronic complications related to transvenous 
or epicardial leads and inappropriate shocks. High defibrillation thresholds at implant and 
follow-up are seen (Stephenson et al., 2006). Changing device position from abdominal to a 
supradiaphragmatic site may solve unsafe elevated discharge impedance and defibrillation 
threshold during follow-up (Berruezo et al., 2010). The best device configuration reported by 
Bardy et al., 2010, consisted of a parasternal electrode and a left lateral thoracic pulse 
generator. This configuration results as effective as a transvenous ICD for terminating 
induced ventricular fibrillation, albeit with a significantly higher mean energy requirement 
(35J vs. 11J). 100% ventricular fibrillation detection and 98% cardioversion effectiveness in 
two consecutive tests confirms its good performance. 100% appropriate shocks have been 
reported for treating ventricular tachycardia during 10-months follow-up. A low rate of 
adverse events confirms its safety.  
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The wearable cardiac defibrillator is an alternative for patients at risk for sudden death who 
do not fulfill standard criteria for defibrillator implantation or in whom the risk:benefit ratio 
is equivocal (Everitt et al., 2010). Careful patient selection and education result essential to 
ensure safety, as noncompliance with wear is common.  
3.3 Procedural complications 
Implantation procedure complications appear between 14% and 26% (Alexander et al., 
2004), (Shah et al., 2009) (Stefanelli et al., 2004). These include pocket infections, pocket 
hematoma, microdislodgement requiring lead manipulation and electromechanical 
dissociation. Early electrode dislocation may need reintervention. In young patients, 
transvenous leads of implantable defibrillator can cause vascular obstruction up to 13%, 
mainly asymptomatic (Bar-Cohen et al., 2006). Local infection increasing rate may be due to 
early activity resume and impaired sterile conditions of wound (Link et al., 1999). Most 
pocket infections are related to local contamination at the time of implantation. Cardiac 
perforation (Morrison et al., 2009), hemothorax or superior Vena Cava syndrome have been 
described as implantation early and late complications (Alexander et al., 2010). 
Postpericardiotomy syndrome is described related to epicardial leads (Stefanelli et al., 2002). 
No pediatric death has been reported related to implantation procedure. 
4. Long-term follow up 
4.1 Therapy history 
Pediatric defibrillator recipients have significant appropriate shock rates. Antitachycardia 
pacing therapy is rarely effective and often harmful in young ICD recipients, because this 
therapy is effective in monomorphic ventricular tachycardia, a rare arrhythmia among  
 
 
Fig. 5. Appropriate shock delivery for ventricular fibrillation in an 11-years-old female child 
with hypertrophic cardiomyopathy. See instability in the cycle length of the sensed 
ventricular electrograms. 
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children. In most patients, programming ICD for only VF therapy is sufficient. A significant 
increased rate of appropriate discharges was found in defibrillator devices placed for 
secondary prevention (52%) versus primary prevention (14%) at 5 years (Von Berger et al., 
2011). Therefore, the benefits of an implantable cardioverter-defibrillator remain greater in 
secondary than in primary prevention patients. In patients with nontransvenous systems, 
up to 23% receive appropriate shocks (Rabdill et al., 2010). In the Dutch registry, rate of 
appropriate shocks were reported at 31%, with a significant difference according to patient 
age (55% for patients under 12 years, 9% for patients between 13 and 18 years old). No 
difference has been reported in secondary prevention related to age, with rates of 
approximately 38% appropriate shocks for both groups (Heersche et al., 2010). In a registry 
of Long QT syndrome from 2002 to 2009, at least 1 appropriate shock was received by 28% 
of patients during 4 years mean follow-up. 
4.2 Device-related complications 
Inappropriate discharges, lead-related complications and generator anomalies are the 
commonest adverse events occurring during follow-up. Lead complications are related to 
high physical activity and body surface, significantly higher in patients with body area 
under 1.2 m2 (OR 4.5) (Shah, 2009). Lewandoski et al., 2010 reported 21% complications 
requiring surgical intervention. In our series, we describe 20% of inappropriate discharges, 
20% lead complications and 10% generator anomalies. In the Long-QT-syndrome registry 
from 2002 to 2009, adverse events occurred in 25% (Schwartz et al., 2009). Serious 
psychological sequel may reach 43%of patients (Lewandowski et al., 2010).  
4.2.1 Inappropriate therapy 
Inappropriate discharges are frequent, some of them caused by suboptimal pre-discharge 
programming of the device (Lewandowski et al., 2010). Reported rates vary sharply in infant 
series, from 11% to 50% (Botsch et al., 2007), being better defined in adult series (20-30%). 
Inappropriate shocks occur in the setting of sinusal and supraventricular tachycardia, QRS 
double-sensing or T-wave oversensing (Korte et al., 2004). Lewandoski et el., 2010 reported 
inappropriate therapy resulting from T-wave over-sensing in 14%, sinus tachycardia in 5%, 
fast atrial fibrillation in 8%, and lead insulation disruption in 1%. Several algorithms have 
been used to reduce inappropriate discharges, as QRS discrimination or cardiac rate stability 
(Barry et al., 2001). In a multicentric series of 210 young defibrillator recipients from seven 
institutions, no differences were found in the risk of inappropriate discharges between 
primary and secondary prevention defibrillators, both rates estimated at approximately 35% 
within 5 years from implant (Berul et al., 2008). In the Dutch registry, 27% shocks deliveries 
were inappropriate. In patients with nontransvenous systems, up to 18% receive 
inappropriate shocks (Rabdill et al., 2010). Congenital patients have higher risk of 
inappropriate discharges (Williams et al., 1998). A higher rate of inappropriate shocks has 
been reported in the setting of lead failure than in other conditions causing inappropriate 
therapies. 
4.2.2 Lead and generator specific complications 
As a general rule, less leads implanted in children, less complication will occur in the 
future, and the simplest system (generally, single-chamber), the better outcome (Silvetti et 
al., 2009).  
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The second most frequent ICD system-related adverse effect in the pediatric population is 
ICD lead failure. Lead failures requiring programming or revision interventions have been 
reported in the range of 7–30% at median follow-up of 2 years in the pediatric literature 
(Stefanelli et al., 2002 & Berul et al, 2008).  
 
 
Fig. 6. Inappropriate shock during sinus tachycardia. See the progressive increase of heart 
rate, stability of cycles length and no further effect of defibrillation discharge. 
In the Netherlands Registry, overall complications occurred in 17% patients, 87% related to 
lead failure (Heersche et al., 2010). Rate of total unanticipated interventions in the 
nontransvenous group is estimated at 18 per 1.000 person-months versus 6 per 1,000 person-
months in the transvenous group (Rabdill et al., 2010). Survival rates for defibrillator leads 
in children are reported in 89.6% at 5-year, when implantation is made by an expertise 
operator. Lead failures as lead fraction and insulation failure (Bennett & Tung, 2010) occur 
mostly within the second year of implantation (Lewandowski et al., 2010). An increase in 
size was associated with higher risk for lead failure as the proximal shocking electrode ends 
to become stretched and distorted, leading to lead failure. 
Given the finite longevity of current lead designs, lead extraction is an eventuality for a 
significant subset of pediatric defibrillator patients. Generator elective replacement is the 
most frequent indication for generator change in the majority of pediatric series. 
Longevity is estimated at more than 9 years for a single-chamber defibrillator without 
permanent pacing, 7 years for a dual-chamber defibrillator pacing 50% of time and 6 years 
for a resynchronization-defibrillator (Bonney et al., 2010), in clinical practice the predicted 
generator survival is hardly accomplished. 
Apart from lead durability, main indications for removal are vascular obstruction (that 
requires simultaneous revascularization), increased thresholds, and lead dislocations 
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(Welisch et al., 2010). Other complications affecting generator are prolonged charge time, 
early battery depletion, and malfunction during implant testing. 
In Dutch series of Harkell et al., 2006, generator replacement was necessary in 18% of 
patients between 28 and 54 months from implantation. Procedural complications rates are 
low, according to a review of 203 lead extractions carried out between 2002 and 2008 
(Cecchin et al., 2010). No procedure deaths were seen in this series, although removal of 
non-functional leads bears the risk of vascular disrupture and embolizations. Of this 
series, 60% of patients had structural heart disease and successful simple extraction was 
only achievable in 29% of patients (requiring just a nonlocking stylet). Complex extraction 
techniques include radiofrequency-powered sheath (Zartner et al., 2010). Successful 
extraction was performed in 80% of all leads and 94% of complex extraction leads 
(Cecchin et al., 2010). Complications were observed in 5% of patients. Older leads, 
intraventricular location, and polyurethane insulation were associated with an increased 
probability of complex extraction. Procedure and x-ray duration correlated to correlated 
to time from lead implantation. 
Cardiac device endocarditis is an infrequent, but potentially lethal complication. 
Hematogenous seeding of Staphilococcus aureus from a distant focus is the most common 
etiology in late infections. Cure is achievable in the large majority of patients under an 
aggressive antimicrobial regime and complete device removal. When the intravascular 
portion of the lead system cannot be aseptically separated from the pocket, removal of the 
entire system is essential (Shah, 2009). After device explantation and long-term standard 
antibiotic treatment to decrease risk for recurrent endocarditis, reimplantation requires 
additional caution (Mihalcz et al., 2008). 
Industry advisories and recalls have an adverse economic, psychosocial and physical impact 
on pediatric defibrillator patients. Between 2000 and 2005, 25% of implanted defibrillators 
were affected by industry advisories or recalls (Mahajan et al., 2008), which meant 22% 
patients undergoing explantation after three years from implant. Just 2 of 89 explanted 
devices were defective, with loose headers as the unique failure observed.  
4.2.3 Progressive increase in defibrillator thresholds 
Failure of first cardioverter-defibrillator shock to terminate ventricular tachycardia or 
fibrillation was reported in 7% of pediatric defibrillator recipients during follow-up, mainly 
due to chronic rise in defibrillation thresholds (Stefanelli et al., 2002). Rates of significant 
changes of defibrillation thresholds range 3,2 to 12% (Stephenson et al., 2006 & Brodsky et 
al., 1999). Epicardial and subcutaneous systems are more likely to present with this 
complication than transvenous systems.  
4.2.4 Electrical storm 
Real incidence of electrical storm in pediatric patients is unknown, although Alexander et 
al., 2004 reported consecutive appropriate shocks in 6% patients. Antiadrenergic medical 
therapy and amiodarone have been used to treat this complication. Morbidity and 
hospitalization are direct consequences of this complication. 
4.2.5 Death rates 
The majority of reported deaths in the pediatric ICD patients appear to be related to 
intractable arrhythmias. Silka et al., 1991 reported 4% sudden death, 1% due to recurrent 
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ventricular arrhythmias. Alexander et al., 2004 observed 2% sudden deaths in patients with 
cardioverter-defibrillator, one of them due to intractable ventricular arrhythmia. 
 
Adverse events reported in cardioverter-
defibrillator pediatric patients 
%
Implantation-related: 
 Pocket complications: hematoma, infection 
 Lead dislocation 
 Cardiac perforation 
 Hemothorax 
 Venous thrombosis 
14-26
13
Mid and long term follow-up: 
 Inappropriated shocks 
 Lead failure 
 Generator failure (recalls, advisories) 
 Increased defibrillation thresholds 
 Electrical storm 
 Death 
11-50
7-30
3-12
2
Table 3. Early and late complications observed in pediatric defibrillators patients. From 
Shah, 2009. Blanck-spaces refer to unknown rates. 
5. Cost-effectiveness study 
Altough more common in adult population, cost-effectiveness studies in pediatric patients 
are scarce. Because of differences in heart failure etiology, sudden death rates, and 
defibrillator complication rates, addition of a prophylactic cardioverter-defibrillator to 
conventional medical management has resulted not cost-effective in children with dilated 
cardiomyopathy, poor ventricular function, and symptomatic heart failure (Feingold et al., 
2010). Total costs were estimated at $433,000 for the defibrillator strategy and $355,000 for 
the medical management. Although quality adjusted survival was greater in the defibrillator 
group, the defibrillator strategy was cost-effective only when the annual probability of 
sudden death exceeded 13%. The low sudden death rates in this population may justify the 
results. No data is available for other cardiac conditions that may benefit more clearly from 
the implantation of a cardioverter-defibrillator in pediatric population.  
6. Quality of life in children with implantable cardioverter-defibrillator 
Psychosocial and quality-of-life outcomes in pediatric patients with implantable 
cardioverter-defibrillators are poorer than in adult population. Anxiety and depression are 
highly related to defibrillator therapies. Shock-related anxiety is suspected to be particularly 
common (Sears et al., 2011). The PedsQL, the Device Severity Index, the ICD and Avoidance 
Survey provide data about Quality-Of-Life. Pediatric defibrillator patients have similar 
Quality-Of-Life outcomes to chronic ill children, with exception of lower physical Quality-
Of-Life. Parent-observed reports show lower psychosocial and physical QOL than reported 
by children themselves. Up to 85% of children present with avoidance behaviors from 
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cardioverter-defibrillation implantation, with female children avoiding places more than 
male. Similar to adult samples, female patients reported lower psychosocial, physical, and 
cardiac Quality-Of-Life scores. Differently from other series, Sears et al. did not find 
discharges and medical severity affecting Quality-Of-Life negatively (Sears et al., 2009).  
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